Efficacy and safety of (Sacubitril-Valsartan) Combination on Patients With congestive Heart Failure

Background: Heart failure with the preserved expulsion fraction accounts for up to half of the cases of heart failure, is linked to significant morbidity and death. This research aims at assessing the bio-clinical effects of the combination of sakubitril and valsartan in the treatment of congestive patients. Methods: A total of 200 patients in this research were split into two groups: in Group A there were 100 cases started with sacubitril/valsartan; and in Group B there were the remaining 100 cases treated with valsartan alone. All patients have been submitted to comprehensive history, physical examination and standard laboratory testing. In addition, echocardiography and MRI were used to evaluate the left ventricular function. The bio-clinical impact of the sakubitril/valsartan combination after 6 months of therapy is measured via various measures, including NYHA class, inpatient frequency, BNP levels, and left-ventricular systolic function. Results: Basal NYHA classes were similar before treatment across the two groups. After therapy, the NYHA class in the combined group improved significantly (group A). Although there was no significant difference in baseline proPNB between the two groups (971,66 and 1021,41 pg/ml respectively in Groups A and B), the marker decreased significantly after treatment (526,71 vs 757,15 pg/ ml in the other group). Conclusion; in patients with heart failure with decreased expulsion fraction, sacubitril/valsartan is linked with a superior recovery profile. It is linked with a substantial increase in EF, a significant drop in proBNP and a reduction in hospitalisation rates.